Alpine Immune Sciences Inc Stock News

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 12% and 12.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Endo (ENDP) delivered earnings and revenue surprises of 50% and 1.73%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflamma

Implementing an appropriate strategy would capture the most profits. One such strategy is diversification. A promising stock for your portfolio to diversify is Alpine Immune Science. As a rising leade

Alpine Immune Sciences Inc (NASDAQ: ALPN) announced the oral presentation of results from the dose-escalation portion of NEON-1 study of davoceticept monotherapy in advanced malignancies. The data

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Aeglea Shares Additional Phase 3 Data In Inherited Metabolic Disease Aeglea BioTherapeutics Inc (NAS

Alpine Immune Sciences, Inc. (ALPN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further

Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -100% and 45.18%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for th

Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -100% and 45.18%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for th

Alpine Immune Sciences, Inc. (ALPN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alpine Immune Sciences (ALPN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Alpine Immune Sciences, Inc. (ALPN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The FDA places a partial clinical hold on Alpine's (ALPN) NEON-2 study evaluating the combo of davoceticept plus Merck's Keytruda for treating advanced malignancies. Shares fall.

The FDA places a partial clinical hold on Alpine's (ALPN) NEON-2 study evaluating the combo of davoceticept plus Merck's Keytruda for treating advanced malignancies. Shares fall.

The FDA has placed a partial clinical hold on Alpine Immune Sciences Inc''s (NASDAQ: ALPN ) NEON-2 trial evaluating davoceticept (ALPN-202) in combination with pembrolizumab in adults with advanced malignancies. The partial clinical hold was prompted by Alpine''s report of patient death in the NEON-2 trial. The participant had choroidal melanoma previously treated with nivolumab and … Full story available on Benzinga.com